Monitor SAFEGUARD enrollment completion and topline data in 2H 2027 for the next binary catalyst.
Price Chart
Executive Summary
SAB Biotherapeutics announced FDA Fast Track designation for SAB-142, its disease-modifying immunotherapy for Stage 3 type 1 diabetes. The designation facilitates expedited development and review, and the registrational Phase 2b SAFEGUARD study is expected to complete enrollment in Q4 2026 with topline data in 2H 2027. This is a positive regulatory milestone for a clinical-stage biotech with no approved products or reported revenue.
Key Facts
- FDA granted Fast Track designation for SAB-142 in Stage 3 type 1 diabetes on October 13, 2026.
- SAB-142 is a potentially disease-modifying fully human anti-thymocyte immunoglobulin (hATG).
- Registrational Phase 2b SAFEGUARD study enrollment expected to complete in Q4 2026.
- Topline data from SAFEGUARD anticipated in 2H 2027.
- Investigator-led Phase 3 PRISE-hATG study is also ongoing.
Financial Impact
No financial figures disclosed; Fast Track designation is a regulatory milestone that may accelerate development timelines and reduce costs, but does not guarantee approval.
Risk Factors
- SAB-142 is still in clinical development with no guarantee of successful trial outcomes or FDA approval.
- The company is pre-revenue and clinical-stage, with high cash burn risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-419769 |
| Document: sabs-ex99_1.htm | 0001193125-26-419769 |
| Document: 0001193125-26-419769-index-headers.html | 0001193125-26-419769 |
| Document: 0001193125-26-419769-index.html | 0001193125-26-419769 |
| Document: 0001193125-26-419769.txt | 0001193125-26-419769 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 25-NSE | $2.84 | awaiting T+5 | — | $3.07 (+8.10%) |
Oct 13, 2026 14d ago | 8-K | $2.68 $2.88 | ▲ +7.46% | ▲ +8.61% | $3.07 (+14.55%) |
Oct 13, 2026 14d ago | Press Release | $2.68 $2.88 | ▲ +7.46% | ▲ +8.61% | $3.07 (+14.55%) |
Jul 7, 2026 16w ago | 8-K | $3.90 $3.60 | ▼ −7.69% | ▼ −8.24% | $3.07 (−21.28%) |
May 29, 2026 21w ago | Press Release | $3.60 $3.36 | ▼ −6.67% | ▼ −6.37% | $3.07 (−14.72%) |
May 12, 2026 24w ago | Press Release | $3.62 $3.56 | ▲ +1.66% | ▲ +1.74% | $3.07 (+15.19%) |
Mar 19, 2026 31w ago | Press Release | $3.75 $3.85 | ▲ +2.67% | ▲ +4.82% | $3.07 (−18.13%) |
Mar 19, 2026 31w ago | 8-K | $3.78 $3.83 | ▼ −1.32% | ▼ −3.53% | $3.07 (+18.78%) |
Mar 17, 2026 31w ago | Press Release | $3.70 $3.82 | ▼ −3.24% | ▼ −3.96% | $3.07 (+17.03%) |
Mar 17, 2026 32w ago | Press Release | $3.70 $3.82 | ▼ −3.24% | ▼ −3.96% | $3.07 (+17.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers